ArticleScientific reports2018
Systemic and specific effects of antihypertensive and lipid-lowering medication on plasma protein biomarkers for cardiovascular diseases.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Targeted proteomic analyses during combined angiotensin-converting enzyme inhibitor and mineralocorticoid receptor antagonist administration (CARDALIS®) in healthy dogs.Journal of veterinary internal medicine · 2026Article
- Plasma proteomics ofmedRxiv : the preprint server for health sciences · 2026Article
- Multi-omics analyses reveal novel metabolic signatures of post-traumatic deep vein thrombosis in patients with coronary heart disease.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Takotsubo Syndrome: The First Non-Acute Proteomic Analysis by Remote Dried Blood Microsampling.Journal of cardiovascular translational research · 2026Article
- AI-based multiomics profiling reveals complementary omics contributions to personalized prediction of cardiovascular disease.Nature communications · 2026Article
- Association of ventricular-arterial coupling with biomarkers involved in heart failure pathophysiology - the STANISLAS cohort.European journal of heart failure · 2025Article
- Application of Human Plasma/Serum to Cell Culture In Vitro: A Translational Research Approach to Better Define Disease Mechanisms.Clinical and translational science · 2025Review
- Circulating Myokines as Novel Biomarkers for Cardiovascular Diseases.Reviews in cardiovascular medicine · 2024Review
- Proteomic prediction of incident heart failure and its main subtypes.European journal of heart failure · 2024Article
- Article
- A proteogenomic signature of age-related macular degeneration in blood.Nature communications · 2022Article
- Article
- Contribution of rare whole-genome sequencing variants to plasma protein levels and the missing heritability.Nature communications · 2022Article
- Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19.PLoS genetics · 2022Article
- Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer.Translational oncology · 2022Article
- Causal effects of inflammatory protein biomarkers on inflammatory diseases.Science advances · 2021Article
- Circulating Biomarkers and Cardiac Structure and Function in Rheumatoid Arthritis.Frontiers in cardiovascular medicine · 2021Article
- It's in Our Blood: A Glimpse of Personalized Medicine.Trends in molecular medicine · 2021Review
- Whole-genome sequencing analysis of the cardiometabolic proteome.Nature communications · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A large fraction of the adult population is on lifelong medication for cardiovascular disorders, but the metabolic consequences are largely unknown. This study determines the effects of common anti-hypertensive and lipid lowering drugs on circulating plasma protein biomarkers. We studied 425 proteins in plasma together with anthropometric and lifestyle variables, and the genetic profile in a cross-sectional cohort. We found 8406 covariate-protein associations, and a two-stage GWAS identified 17253 SNPs to be associated with 109 proteins. By computationally removing variation due to lifestyle and genetic factors, we could determine that medication, per se, affected the abundance levels of 35.7% of the plasma proteins. Medication either affected a single, a few, or a large number of protein, and were found to have a negative or positive influence on known disease pathways and biomarkers. Anti-hypertensive or lipid lowering drugs affected 33.1% of the proteins. Angiotensin-converting enzyme inhibitors showed the strongest lowering effect by decreasing plasma levels of myostatin. Cell-culture experiments showed that angiotensin-converting enzyme inhibitors reducted myostatin RNA levels. Thus, understanding the effects of lifelong medication on the plasma proteome is important both for sharpening the diagnostic precision of protein biomarkers and in disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.